Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 8—August 2005

Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table A4

Preexposure (seasonal) prophylaxis trials included in the analysis

Trial Age group, y Intervention (no. participants) Treatment duration
Hayden et al., 1999 (11) 18–65 Oseltamivir 75 mg 1×/d (520) 6 weeks
Oseltamivir 75 mg 2×/d (520)
Placebo (519)
Monto et al., 1999 (15) 18–69 Zanamivir 10 mg 1×/d (553) 4 weeks
Placebo (554)

Main Article

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.